NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

The Indian judiciary did well not to let Novo Nordisk extend its exclusive right to sell semaglutide, marketed as Ozempic and ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Novo Nordisk can end the horror year of 2025 on a positive note. The EMA has issued a positive opinion on a higher Wegovy ...

Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

U.S. lawsuits against Novo Nordisk and Eli Lilly alleging patients taking weight loss drugs lost some or all of their ...

Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a ...